Antisense oligonucleotides: An evolving technology for the modulation of gene expression in human disease

Journal of the American College of Surgeons

Volumn 191, Issue 1, 2000, Pages 93-105

  Green, Douglas W ^a   Roh, Haeri ^a   Pippin, James ^a   Drebin, Jeffrey A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; GENE EXPRESSION SYSTEM; GENETIC ENGINEERING; GENETIC MANIPULATION; HUMAN; HUMAN GENETICS; IMMUNOMODULATION; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CROHN DISEASE; GENE EXPRESSION; HUMANS; MOLECULAR BIOLOGY; NEOPLASMS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN BIOSYNTHESIS; PROTO-ONCOGENE PROTEINS C-RAF; RNA, MESSENGER; THIONUCLEOTIDES; TRANSFORMATION, GENETIC; VASCULAR DISEASES;

EID: 0033919203     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1072-7515(00)00305-7     Document Type: Review

References (79)

1. Zamecnik PC, Stephenson ML. Inhibition of Rous Sarcoma Virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 1978;75:280-284.
2. Crooke ST. Advances in understanding the pharmacological properties of antisense ODNs. Adv Pharmacol 1996;40:1-49.
3. Patzel V, Sczakiel G. Theoretical design of antisense RNA structures substantially improves annealing kinetics and efficacy in human cells. Nat Biotech 1998;16:64-68.
4. Milner N, Mir KU, Southern EM. Selecting effective antisense reagents on combinatorial oligonucleotide arrays. Nat Biotech 1997;15:537-541.
5. Mir K, Southern E. Determining the influence of structure on hybridization using oligonucleotide arrays. Nat Biotech 1999;8: 788-792.
6. Wagner RW, Matteucci MD, Grant D, et al. Potent and selective inhibition of gene expression by an antisense heptanucleotide. Nat Biotech 1996;14:840-844.
7. Lonnberg H, Vuorio E. Toward genomic drug therapy with antisense ODNs. Ann Med 1996;28:511-522.
8. Wagner RW. The state of the art in antisense research. Nat Med 1995;1:1116-1118.
9. Stein CA. Does antisense exist? Nat Med 1995;1:1119-1121.
10. Bates PJ, Kahlon JB, Thomas SD, et al. Antiproliferative activity of G-rich oligonucleotides correlates with protein binding. J Biol Chem 1999;274:26369-26377.
11. Stepkowski SM, Tu Y, Condon TP, Bennett CE Blocking of heart allograft rejection by intercellular adhesion molecule-1 alone or in combination with other immunosuppressive modalities. J Immunol 1994;153:5336-5346.
12. Monia BP, Johnston JF, Greiger T, et al. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against c-Raf kinase. Nat Med 1996;2:668-675.
13. Kronewett R, Haas R. Antisense strategies for the treatment of hematological malignancies and solid tumors. Ann Hematol 1988;77:1-12.
14. Higgins KA, Perez JR, Coleman TA, et al. Antisense inhibition of the p65 subunit of NF-kB blocks tumorigenicity and causes tumor regression. Proc Natl Acad Sci USA 1993;90:9901-9905.
15. Webb A, Cunningham D, Cotter F, et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 1997; 349:1137-1141.
16. Maher J, Baker DA, Manning M, et al. Evidence for cell-specific differences in transformation by N-, H-, and K-ras. Oncogene 1995;11:1639-1647.
17. Monia BP, Johnston JE, Ecker DJ, et al. Selective inhibition of mutant Ha-Ras mRNA expression by antisense oligonucleotides. J Biol Chem 1992;267:19954-19962.
18. Cowsert LM. In vitro and in vivo activity of antisense inhibitors of ras: potential for clinical development. Anticancer Drug Des 1997;12:359-371.
19. Monia BP, Johnston JF, Geiger T, et al. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat Med 1996;2:668-675.
20. Monia BP. First and second generation antisense inhibitors targeted to human c-Raf kinase: in vitro and in vivo studies. Anticancer Drug Des 1997;12:327-341.
21. Stevenson J, Yao KS, Gallagher M, et al. Phase I clinical/ pharmacokinetic trial of the c-Raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A). J Clin Oncol 1999;17:2227-2236.
22. McGraw K, McKay R, Miraglia L, et al. Antisense oligonucleotide inhibitors of isozymes of protein kinase C In vitro and In vivo activity, and clinical as anticancer therapeutics. Anticancer Drug Des 1997;12:315-327.
23. Yazaki T, Ahmad S, Chahlavi A, et al. Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide. Mol Pharmacol 1997;50:236-242.
24. Dean N, McKay R, Miraglia L, et al. Inhibition of growth of human tumor cell lines in nude mice by an antisense oligonucleotide inhibitor of protein kinase C-alpha expression. Cancer Res 1996;56:3499-3507.
25. Ways, Kukoly CA, DeVente J, et al. MCF-7 breast cancer cells transfected with PKC-a exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype. J Clin Invest 1995;95:1906-1915.
26. Reed JC. Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Semin Hematol 1997;34[Suppl 5]:9-19.
27. Kitada S, Takayama S, De Riel K, et al. Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Res Dev 1994;4:71-79.
28. Kronenwett R, Haas R. Antisense strategies for the treatment of hematological malignancies and solid tumors. Ann Hematol 1998;77:1-12.
29. Flanagan WM. Antisense comes of age. Cancer Metastasis Rev 1998;17:169-176.
30. Campos L, Sabido O, Rouault JP, et al. Effects of bcl-2 antisense oligonucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells. Blood 1994;84:595-600.
31. Cotter FE, Johnson P, Hall P, et al. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hui mouse model. Oncogene 1997;9:3049-3055.
32. Webb A, Cunningham D, Cotter F, et al. Bcl-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 1997;349: 1137-1141.
33. Schechter AL, Stern DF, Vaidyanathan L, et al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumor antigen. Nature 1984;312:513-516.
34. Coussens L, Yang-Feng TL, Liao Y-C, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985;230:1132-1139.
35. Slamon DJ, Clark GM, Wong Sg, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182.
36. Berchuck A, Kamel A, Whitaker R, et al. Overexpression of HER-2neu is associated with a poor survival in advanced epithelial ovarian cancer. Cancer Res 1990;50:4087-4091.
37. Williams TM, Weiner DB, Greene MI, et al. Expression of c-erbB-2 in human pancreatic adenocarcinomas. Pathobiology 1991;59:46-52.
38. Yonemura Y, Ninomiya I, Ohoyama S, et al. Expression of c-erbB-2 oncoprotein in gastric carcinoma: immunoreactivity for c-erbB-2 protein is an independent indicator of poor short-term prognosis in patients with gastric carcinoma. Cancer 1991; 67:2914-2918.
39. Berchuck A, Rodriguez G, Kinney RB, et al. Overexpression of HER-2neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol 1991;164:15-21.
40. Kern JA, Schwartz DA, Nordberg JE, et al. P185neu expression of human lung adenocarcinomas predicts shortened survival. Cancer Res 1990;50:5184-5187.
41. Katsumata M, Okudaira T, Samanta A, et al. Prevention of breast tumour development in vivo by downregulation of the pl85neu receptor. Nat Med 1995;1:644-648.
42. Shepard HM, Lewis GD, Sarup JC, et al, Monoclonal antibody therapy for human cancer: taking the HER2 proto-oncogene to the clinic. J Clin Oncol 1991;11:117-127.
43. Katsumata M, Okudaira T, Samanta A, et al. Prevention of breast tumor development in vivo by down regulation of the p185 receptor. Nat Med 1995;1:644-648.
44. Roh H, Pippin J, Boswell C, et al. Antisense oligonucleotides specific for HER-2 neu oncogene inhibit the growth of human breast carcinoma cells that overexpress HER-2/neu. J Surg Res 1998;77:85-90.
45. Roh H, Pippin J, Drebin JA. Downregulation of HER2/neu expression by antisense oligonucleotides induces apoptosis in human breast cancer cells that overexpress HER2/neu. Surg Forum 1998 Clinical Congress 49:418-421.
46. Colomer R, Lupu R, Bacus SS, et al. ErbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cell lines with erbB-2 oncogene amplification. Br J Cancer 1994;70:819-825.
47. Boswell C, Pippin J, Drebin JA. Downregulation of HER2/neu expression using combinations of antisense oligonucleotides and monoclonal antibodies results in enhanced antitumor effects. Surgical Forum 1998;49:456-458.
48. Dilley RJ, McGeachie JK, Prendergast FJ. A review of the proliferative behaviour, morphology and phenotypes of vascular smooth muscle. Atherosclerosis 1987;63:99-107.
49. McBride W, Lange R, Hillis L. Restenosis after successful coronary angioplasty: pathophysiology and prevention. N Engl J Med 1988;318:1734-1737.
50. Pollman MJ, Hall JL, Mann MJ, et al. Inhibition of neointimal cell bcl-x expression induces apoptosis and regression of vascular disease. Nat Med 1998;4:222-227.
51. Simons M, Rosenberg RD. Antisense nonmuscle myosin heavy chain oligonucleotides suppress smooth muscle proliferation in vitro. Circ Res 1992;70:835-843.
52. Simons M, Edelman ER, Dekeyser J, et al. Antisense c-myb ODNs inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature 1992;359:67-70.
53. Shi Y, Fard A, Galeo A, et al. Cellular, molecular, biological, and immunological research: transcatheter delivery of c-myc antisense oligomers reduces neointimal formation in a porcine model of coronary artery balloon injury. Circulation 1994;90: 944-951.
54. Suzuki J, Isobe M, Morishita R, et al. Prevention of coronary arteriosclerosis by antisense cdk2 kinase oligonucleotide. Nat Med 1997;3:900-903.
55. Poston R, Ennen M, Pollard J, et al. Ex vivo gene therapy prevents chronic graft vascular disease in cardiac allografts. J Thorac Cardiovasc Surg 1998;116:386-396.
56. Nakamura S, Ohtani H, Watanabe Y, et al. In situ expression of the cell adhesion molecules in inflammatory bowel disease. Evidence of immunologic activation of vascular endothelial cells. Lab Invest 1993;69:77-85.
57. Bennett CF, Kornbrust D, Henry S, et al. An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice. J Pharmacol Exp Ther 1997;280:988-1000.
58. Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, et al. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology. 1998;114: 1133-1142.
59. Stephenson ML, Zamecnik PC. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sei USA 1978;75:285-288.
60. Zamecnik PC, Goodchild Y, Taguchi Y, et al. Inhibition of replication and expression of human T-cell lymphocytic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA. Proc Natl Acad Sci U S A 1986; 83:4143-4146.
61. Matsukura M, Zon G, Shinozuka K, et al. Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev(art/trs) in chronically infected cells. Proc Natl Acad Sci USA 1989;86:4244-4248.
62. Offensperger WB, Offensperger S, Walter E, et al. In vivo inhibition of duck hepatitis B replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides. EMBO J 1993;12:1257-1262.
63. Wu GY, Wu CH. Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense ODNs. J Biol Chem 1992;267:12436-12439.
64. Cowsert LM, Fox MC, Zon G, et al. In vitro evaluation of phosphorothioate ODNs targeted to the E2 mRNA of papillomavirus: potential treatment for genital warts. Antimicrob Agents Chemother 1993;37:171-177.
65. Bouille P, Subra F, Mouscadet JF, et al. Antisense-mediated repression of DNA topoisomerase II expression leads to an impairment of HIV-1 replicative cycle. J Mol Biol 1999;285:945-954.
66. Veal GJ, Agrawal S, Bryn RA. Sequence specific Rnase H cleavage of gag mRNA from HIV-1 infected cells by an antisense oligonucleotide in vitro. Nucleic Acids Res 1998;26:5670-5675.
67. Mestre B, Arzumanov A, Singh M, et al. Oligonucleotide inhibition of the interaction of HIV-1 Tat protein with the transactivation responsive region (TAR) of HIV RNA. Biochim Biophys Acta 1999;1445:86-98.
68. Sereni D, Tubiana R, Lascoux C, et al. Pharmacokinetics and tolerability of intravenous trecovirsen (GEM 91), an antisense phosphorothioate oligonucleotide, in HIV-positive subjects. J Clin Pharmacol 1999;39:47-54.
69. Perillo RP, Schiff ER, Davie GL, et al. A randomized, controlled trial of interferon alfa-2B alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990; 323:295-301.
70. Perry CM, Balfour JA. Fomivirsen. Drugs 1999;57:375-380.
71. Putnam DA. Antisense strategies and therapeutic applications. Am J Health Syst Pharm 1996;53:151-160.
72. Ho P, Parkinson DR. Antisense ODNs as therapeutics for malignant diseases. Semin Oncol 1997;24:187-202.
73. Calabretta B, SkorskiT, Ratajczak MZ, et al. Antisense strategies in the treatment of leukemias. Semin Oncol 1996;23:78-87.
74. Geary RS, Leeds JM, Henry SP, et al. Antisense oligonucleotide inhibitors for the treatment of cancer: 1. pharmacokinetic properties of phosphorothioate oligonucleotides. Anticancer Drug Des 1997;12:383-393.
75. Henry SP, Monteith DK, Levin AA. Antisense oligonucleotide inhibitors for the treatment of cancer: 2. toxicological properties of phosphorothioate oligonucleotides. Anticancer Drug Des 1997;12:395-407.
76. Shaw DR, Rustagi PK, Kandimala ER, et al. Effects of synthetic oligonucleotides on human complement and coagulation. Biochem Pharmacol 1997;53:1123-1132.
77. Zhang R, Yan J, Shahinian H, et al. Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-inrected subjects. Clin Pharmacol Ther 1995;58:44-53.
78. Henry SP, Monteith D, Bennett F, Levin AA. Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-a and c-raf kinase. Anticancer Drug Des 1997;12:421-431.
79. Tortora G, Caputo R, Damiano V, et al. Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed back-bone antisense oligonucleotide targeting protein kinase A. Proc Natl Acad Sci USA 1997;94:12586-12591.